Krystal Biotech, Inc. $KRYS Shares Sold by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 12.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,695 shares of the company’s stock after selling 251 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Krystal Biotech were worth $233,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after acquiring an additional 365,304 shares during the period. Braidwell LP boosted its stake in Krystal Biotech by 99.9% during the 1st quarter. Braidwell LP now owns 400,744 shares of the company’s stock worth $72,254,000 after purchasing an additional 200,244 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Krystal Biotech by 3.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock worth $45,168,000 after purchasing an additional 7,344 shares during the last quarter. Nuveen LLC acquired a new stake in Krystal Biotech during the 1st quarter worth $42,223,000. Finally, Woodline Partners LP grew its holdings in Krystal Biotech by 0.4% in the 1st quarter. Woodline Partners LP now owns 222,043 shares of the company’s stock valued at $40,034,000 after buying an additional 941 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Down 0.2%

KRYS opened at $186.13 on Friday. The stock’s 50-day moving average price is $164.99 and its 200 day moving average price is $152.07. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84. The firm has a market cap of $5.39 billion, a price-to-earnings ratio of 37.83 and a beta of 0.64.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Guggenheim set a $224.00 target price on Krystal Biotech and gave the company a “buy” rating in a report on Friday, October 17th. Chardan Capital decreased their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a research note on Friday, August 22nd. Bank of America upped their price target on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. HC Wainwright reaffirmed a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Monday, September 15th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $223.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).